Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Company Information
About this company
Key people
Jian Irish
President, Chief Executive Officer, Director
Brian C. Thomas
Co-Founder, Director
Pamela M. Wapnick
Chief Financial Officer
Matthew L. Wein
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
Sarah B. Noonberg
Chief Medical Officer
Willard H. Dere
Independent Chairman of the Board
Laurence E. Reid
Director
Eric H. Bjerkholt
Independent Director
Juergen Eckhardt
Independent Director
Click to see more
Key facts
- Shares in issue37.55m
- EPICMGX
- ISINUS59102M1045
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$54.42m
- Employees124
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.